Minerva Neurosciences(NERV)
BURLINGTON, MABiotechnology
Focus: Minerva Neurosciences is a public biotechnology company focused on CNS treatments, specifically targeting neurology indications like schizophrenia and depression. The company operates at a modest scale with 7 active clinical programs in early-to-mid stage development.
Profile data last refreshed 1h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
8+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at Minerva Neurosciences?
AI assessmentHigh-risk, high-reward CNS play suitable only for specialists willing to accept restructuring or financing risk in exchange for early Phase 3 exposure.
Why Work Here
- Lead two Phase 3 programs (Roluperidone and Placebo Oral Tablet for schizophrenia negative symptoms) with near-term regulatory catalysts
- Focused CNS portfolio limits distractions and builds deep expertise in high-unmet-need psychiatric indications
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Pipeline & Clinical Trials
MIN-101
SchizophreniaClinical Trials (1)
NCT02232529Pharmacokinetic Study of MIN-101 in Healthy Subjects
Phase 1Help build intelligence for Minerva Neurosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.